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A variety of circumstantial evidence from humans has implicated the B cell antigen receptor (BCR) in the genesis of B
cell lymphomas. We generated mouse models designed to test this possibility directly, and we found that both the
constitutive and antigen-stimulated state of a clonal BCR affected the rate and outcome of lymphomagenesis initiated
by the proto-oncogene MYC. The tumors that arose in the presence of constitutive BCR differed from those initiated by
MYC alone and resembled chronic B cell lymphocytic leukemia/lymphoma (B-CLL), whereas those that arose in
response to antigen stimulation resembled large B-cell lymphomas, particularly Burkitt lymphoma (BL). We linked the
genesis of the BL-like tumors to antigen stimulus in three ways. First, in reconstruction experiments, stimulation of B
cells by an autoantigen in the presence of overexpressed MYC gave rise to BL-like tumors that were, in turn, dependent
on both MYC and the antigen for survival and proliferation. Second, genetic disruption of the pathway that mediates
signaling from the BCR promptly killed cells of the BL-like tumors as well as the tumors resembling B-CLL. And third,
growth of the murine BL could be inhibited by any of three distinctive immunosuppressants, in accord with the
dependence of the tumors on antigen-induced signaling. Together, our results provide direct evidence that antigenic
stimulation can participate in lymphomagenesis, point to a potential role for the constitutive BCR as well, and sustain
the view that the constitutive BCR gives rise to signals different from those elicited by antigen. The mouse models
described here should be useful in exploring further the pathogenesis of lymphomas, and in preclinical testing of new
therapeutics.
Citation: Refaeli Y, Young RM, Turner BC, Duda J, Field KA, et al. (2008) The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell
lymphomas. PLoS Biol 6(6): e152. doi:10.1371/journal.pbio.0060152
Introduction
Malignancies affecting the B cell lineage comprise the vast
majority of human lymphomas [1]. There are at least 15
different types of B cell lymphomas (BCLs), differing in
clinical behavior, biological phenotype, pathogenesis, and
response to treatment. Irrespective of their type, however,
most BCLs share two features: chromosomal translocations
that involve an immunoglobulin gene and one or another
proto-oncogene [2], and expression of a B cell antigen
receptor (BCR). Chromosomal translocations have long been
considered crucial to the pathogenesis of the tumors. But
there is now increasing evidence that signaling from the BCR
may be a coconspirator in that pathogenesis (for a review, see
[3]).
A BCR is expressed on normal B cells throughout the
course of their development, and this expression appears to
be essential for survival of the cells [4]. There is controversy,
however, about whether the life-sustaining signal from the
BCR is autogenous in nature or arises from antigenic stimulus
[5]. The BCR expressed by BCLs is also apparently required
for survival of the tumor cells and may drive cellular
proliferation [6].
More than 40 years ago, Damashek and Schwartz proposed
that antigenic stimulus might contribute to the genesis of
BCLs in the context of autoimmune disease [7]. In the
interim, circumstantial evidence has mounted to support a
role for antigen stimulation in diverse forms of lymphoma-
genesis. For example, in some instances, the structure of the
BCR on BCLs shows evidence of having been subjected to
antigen selection [8–14], and may even bind a known
antigen—either a protein encoded by a virus suspected of
being an etiological agent, or an autoantigen [15,16].
We sought to test directly the role of the BCR in the genesis
of BCLs by reconstruction in mouse models. We used a series
of transgenic mice that allowed cooperation between either
the constitutive or antigen-activated BCR with the proto-
oncogene MYC, the activation of which by chromosomal
translocation has been implicated in the genesis of human
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[17–19]. We derived these models from two strains of mice
that express transgenes of MYC in the lymphoid lineage. In
one strain (El-MYC), transcription of the transgene is driven
by the control element for the immunoglobulin heavy chain
gene [20]; in the other strain (MMTV-rtTA/TRE-MYC), the
MYC transgene is also transcribed in the B cell lineage, but
the transcription is governed by a tetracycline responsive
control element and can be repressed by administration of
tetracycline or an analogue, doxycycline [21–23].
We modiﬁed these transgenic strains so that their B-cell
repertoire was dominated by a mature BCR for the antigen
hen egg lysozyme (HEL), by breeding in a transgene for that
receptor (BCR
HEL), whose expression was targeted to the B
cell lineage [24]. We could then provide an antigenic stimulus
by breeding in a transgene that produced a soluble version of
the normally membrane-bound antigen (sHEL) [25]. This set
of mouse models allowed us to examine whether either
autogenous or antigen-induced signaling from the BCR could
cooperate with overexpressed MYC in the initiation and
maintenance of BCLs.
Our results suggest that both forms of signaling from the
BCR can cooperate with overexpressed MYC in tumori-
genesis. The tumors that arose in mice expressing both
BCR
HEL and sHEL differed from those found in El-MYC
mice, and bore a striking resemblance to BL. Reconstruction
experiments demonstrated that both the survival and
proliferation of these tumors was dependent upon the
cognate autoantigen for the BCR. We also found that BCR
HEL
itself could cooperate with MYC in tumorigenesis. The
resulting tumors differed from both those in the El-MYC
mice and those in El-MYC/BCR
HEL/sHEL mice, and re-
sembled a subset of chronic B-cell lymphocytic leukemia (B-
CLL). We attribute the phenotype of the El-MYC/BCR
HEL
tumors to autogenous signaling from the BCR [4, 26]. The
requirement for continuous BCR signals in the maintenance
of either the murine BL-like tumors or the B-CLL–like
tumors was authenticated by genetic and pharmacological
disruption of signaling from the BCR.
Our ﬁndings provide experimental support for previous
suggestions that both autogenous and antigen-stimulated
signaling from the BCR can contribute to lymphomagenesis;
provide a direct demonstration that autoantigenic stimula-
tion can contribute to lymphomagenesis; and sustain the view
that the constitutive BCR gives rise to autogenous signals that
differ from those elicited by antigen. This is also the ﬁrst
report, to our knowledge, in which the potential contribu-
tions of constitutive and antigen-stimulated BCR to lympho-
magenesis are compared. The models that are dependent
upon autoantigenic stimulation bear a close resemblance to
human large BCLs, and to BL, in particular. The results also
raise the possibility that interruption of signaling from the
BCR may have therapeutic value in the treatment of BCLs
that express the receptor. The animal models described here
should be useful in exploring further the pathogenesis of
lymphomas and in preclinical testing of new therapeutics for
lymphomas.
Results
Introduction of Antigen Specificity into B Cells Expressing
a Transgene for MYC
To test the role of BCR signaling in lymphomagenesis, we
generated mice containing B cells that both overexpressed
MYC and had a known antigenic speciﬁcity at a high
frequency. To that end, we bred a transgene for BCR
HEL
into El-MYC mice, creating a strain designated El-MYC/
BCR
HEL. Expression of the El-MYC and BCR
HEL transgenes
was targeted to the B cell lineage [20,25]. Mice that express
the El-MYC transgene alone appear developmentally normal
at ﬁrst [27], but later accumulate a large number of polyclonal
Pre/Pro-B cells (B220þ, CD43þ, IgM–, IgD–) in their bone
marrow, and eventually also in their peripheral lymphoid
organs, from which a monoclonal Pre/Pro BCL arises [20]. In
contrast, the bone marrow and lymph nodes of El-MYC/
BCR
HEL mice contained normal numbers of mature B cells,
which expressed BCR
HEL on their surface (unpublished data).
Thus, the developmental arrest normally observed in El-MYC
mice was apparently corrected by the introduction of an
antigen receptor transgene, in accord with previous results
[28]. The El-MYC/BCR
HEL mice provided a means to test for
cooperation between signaling from the BCR and over-
expression of MYC in the genesis of lymphoid tumors.
Expression of BCR
HEL in the B Cell Lineage Altered
Lymphomagenesis by MYC
The El-MYC/BCR
HEL mice developed fatal lymphomas
more rapidly than did El-MYC mice (Figure 1A), and the
anatomical distribution of the tumor was different (Figure 2).
These observations are based on the detailed analysis of
tumor that arose in 80 individual mice, maintained in three
different animal facilities in two institutions. We consistently
observed this phenotype in the tumors, in spite of previous
reports of some low frequency of mature B cell malignancies
[29,30]. The emergence of tumors was followed in three ways:
by anatomical inspection, by counting the total number of
cells in organs (Figure 2), and by ﬂow cytometric analysis to
enumerate B cells carrying BCR
HEL (Figure S1).
Evidence of tumor in El-MYC/BCR
HEL mice appeared ﬁrst
in the spleen at about 18 wk of age, then in lymph nodes and
the bone marrow. Histological examination of the tumors
revealed a diffuse and homogeneous population of small
lymphocytes (Figure 3C and 3H). Analysis with a panel of cell-
surface markers identiﬁed the tumor cells as mature but naı ¨ve
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Author Summary
It has long been suspected that the malignant proliferation of B
lymphocytes known as lymphomas might represent a perversion of
how the cells normally respond to antigen. In particular, the
molecular receptor on the surface of the cells that signals the
presence of antigen might be abnormally active in lymphomas. We
have tested this hypothesis by engineering the genome of mice so
that virtually all of the B cells are commandeered by a single version
of the surface receptor, then stimulated that receptor with the
molecule it is designed to recognize. Our results indicate that both
the unstimulated and stimulated states of the receptor can
cooperate with an oncogene known as MYC in the genesis of
lymphomas. But the two states of the receptor give rise to different
forms of lymphoma. In particular, the stimulated form cooperates
with MYC to produce a disease that closely resembles Burkitt
lymphoma. These results illuminate the mechanisms that are
responsible for lymphomas and could inform the development of
new strategies to treat the disease.B cells, reminiscent of those found in a subset of human B-
CLL (Table 1 and Figure S1), whereas the El-MYC tumors
were composed of Pre/Pro B-cells (Table 1, in accord with
[20]). In addition, the tumors in El-MYC/BCR
HEL mice appear
to be mature naı ¨ve B cells that are CD5–. In human B-CLL,
the two main subsets are CD5þand CD5–. Tumors composed
of mature, naı ¨ve B cells also arose in MMTV-rtTA/TRE-MYC/
BCR
HEL mice that had not been exposed to doxycycline
(unpublished data). Those mice overexpress MYC from a
different control element, but developed the same sort of
tumors as observed with the El-MYC/BCR
HEL transgenes
(Table 1 and Table S1). We conclude that a constitutive BCR
can cooperate with MYC in the genesis of BCLs and can elicit
a distinctive phenotype in the tumor cells. We attribute the
ﬁndings to a previously described form of autogenous
signaling from the BCR [4,26] (See Discussion).
Antigenic Stimulation Altered Lymphomagenesis by MYC
To explore how antigen stimulation of BCR
HEL might
affect tumorigenesis by MYC, we bred a ubiquitously ex-
pressed transgene for sHEL into the El-MYC/BCR
HEL back-
ground. The resulting strain (El-MYC/BCR
HEL/sHEL)
developed tumors even more rapidly than did El-MYC/
BCR
HEL mice (Figure 1A).
Overgrowth of B cells could be detected in the bone
marrow, lymph nodes, spleen, and thymus (Figure 2). B cells
also inﬁltrated the liver, lungs, and central nervous system.
Compression and invasion of the spinal cord caused paralysis
of the hind and fore limbs. Histological examination revealed
a homogeneous population of large lymphocytes in the
spleen, lymph nodes, thymus, and bone marrow. The sheets
of cells had a ‘‘starry sky’’ appearance (Figure 3D and 3I) that
is common among large BCLs and is a prominent feature of
BL [31]. This designation results from the presence of sheets
Figure 1. A Clonal B cell Antigen Receptor Cooperates with MYC in the Development of BCLs
(A) Survival. Strains of mice in groups of 50 were observed over a period of 36 wk. Deceased mice were examined by necropsy. Death was uniformly
attributable to lymphoid tumors. The difference among the mortality curves for the El-MYC/BCR
HEL/sHEL mice and that of MMTV-rtTA/TRE-MYC/BCR
HEL/
sHEL transgenic mice to each other had a significance value p¼0.05. The difference between the mortality curves for those two sets of mice and the
other mice represented in the graph was p¼0.005. In addition, the statistical significance of the difference between the El-MYC/BCR
HEL transgenic mice
and any other groups of mice presented in the graph is p , 0.01.
(B) Jaw tumor in 16-wk-old MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL mouse.
doi:10.1371/journal.pbio.0060152.g001
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Contributions of BCR to B Cell Lymphomagenesisof monomorphic cells interspersed with macrophages that
have engulfed apoptotic cells. When examined for surface
markers, the tumor cells closely resembled mature, activated
B lymphocytes that have experienced the germinal center
(GC). Further evidence for the GC origins of these cells will be
presented below. As expected, the tumor cells were speciﬁc
for HEL, as evidenced by their ability to bind the antigen
(Table 1).
We also bred the BCR
HEL and sHEL transgenes into a
second strain of mice that expresses MYC in the B cell lineage
(MMTV-rtTA/TRE-MYC)(see Introduction and Materials and
Methods). The ﬁnal composite strain was designated MMTV-
rtTA/TRE-MYC/BCR
HEL/sHEL. We originally created these
mice for other purposes, but the manner in which they
developed tumors proved noteworthy for the present con-
text. The mice died somewhat later than the El-MYC/BCR
HEL/
sHEL mice, but earlier than the other strains analyzed in the
present study (Figure 1A). In a striking departure from our
previous experience, however, tumors appeared ﬁrst in the
jaw, in a randomly unilateral manner (Figure 1B). The mice
eventually developed a more generalized disease, with tumor
cells appearing in multiple lymphoid organs and inﬁltrating
nonlymphoid tissues as well (Figure 2 and unpublished data).
We observed this phenotype in 53 of 60 mice that were
analyzed. The remaining seven mice in that cohort of 60
animals was only found to be sick at a very advanced stage of
the disease, so we can not formally state that they initially
presented with a randomly unilateral tumor in the jaw. The
histological appearance of the tumors was similar to that of
the El-MYC/BCR
HEL/sHEL tumors, including a starry sky
appearance (Figure 3E and 3J). The surface phenotype of
MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL tumor cells also re-
sembled that of El-MYC/BCR
HEL/sHEL tumors (Table 1 and
Figure S1). The jaw tumors were covered with a thin layer of
calciﬁed material (unpublished data), a feature not associated
with tumors at other sites or in the other strains of mice. The
endemic form of BL initially presents in a randomly
unilateral manner in the jaw (see Discussion).
In summary, the constitutive and antigen-stimulated forms
of BCR
HEL altered tumorigenesis by MYC in distinctive
manners. The distinctions involved diverse features of the
tumors, including rate of appearance, anatomical presenta-
tion and progression, histopathology, and cell-surface phe-
notype (Table S1). The tumors that arose under the inﬂuence
of a constitutive BCR resembled human B-CLL, whereas those
that developed in the presence of antigen stimulation
resembled BL in multiple ways and were similar in two
strains of mice with different MYC transgenes. Importantly,
our work involves the overexpression of MYC in the context
of autoreactive B cells. The overexpression of MYC is the
characteristic genetic lesion in BL, such that these mouse
models are the most germane to the mechanisms that give
rise to BL.
Tumors Driven by Antigen Receptor Signals Are
Oligoclonal
To determine the clonality of the various tumors, we used
PCR to analyze the VH to DJH rearrangements of the
endogenous IgH genes. The results are summarized in Table
2 and documented in Figure S2. As expected, the data from
spleen cells of normal mice revealed evidence of germ line
IgH genes, as well as innumerable rearranged conﬁgurations.
Similar results were obtained with spleen cells obtained from
an MRL
lpr/lpr mouse with a characteristic lymphoproliferative
disease that involves innumerable B cell clones [32]. In
contrast, tumors derived from the various strains of mice with
MYC transgenes were composed of relatively few clones of B
cells and displayed no evidence of germ line conﬁgurations.
The El-MYC tumors were largely monoclonal (unpublished
data), as reported previously [20]. The El-MYC/BCR
HEL and
El-MYC/BCR
HEL/sHEL tumors contained multiple clones,
with the latter slightly more complex than the former (20–
40 discrete clones for the El-MYC/BCR
HEL tumors, and 10–15
clones for the El-MYC/BCR
HEL/sHEL tumors). Tumors in
both the jaw and other sites of the MMTV-rtTA/TRE-MYC/
BCR
HEL/sHEL mice were also multiclonal, and in any given
animal, the patterns of Ig rearrangement were similar in
tumors from all sites, suggesting that the same group of
neoplastic clones gave rise to all of the tumors in the animal
(unpublished data). The same conservation of clonal patterns
among different organ sites was observed for tumors derived
Figure 2. Lymphomagenesis in Transgenic Mice
Single-cell suspensions were generated from lymph nodes (six nodes for
each mouse – a pair of inguinal, axillary and brachial lymph nodes),
spleens, thymii and jaw-tumors. The bar graphs represent the total
number of cells (x10
 6) obtained for the indicated organs. Counts
represent the mean derived from 10 independent mice 6 the standard
deviation for those values. Healthy animals were euthanized at 21 d of
age, El-MYC mice at 200–240 d, El-MYC/BCR
HEL mice at 112–130 d, El-
MYC/BCR
HEL/sHEL mice at 26–30 d, and MMTV-rtTA/TRE-MYC/sHEL/
BCR
HEL mice at 71–86 d. All tumors contained homogeneous populations
of cells with distinctive surface phenotypes: B220þ/IgM- cells for El-MYC
tumors, B220þ/IgM
aþcells for both El-MYC/BCR
HEL and El-MYC/BCR
HEL/
sHEL tumors, and B220þ/BCR
HEL cells for MMTV-rtTA/TRE-MYC/BCR
HEL/
sHEL tumors. Open bars represent normal mice. Filled bars represent
tumor-bearing mice.
doi:10.1371/journal.pbio.0060152.g002
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Contributions of BCR to B Cell Lymphomagenesisfrom the other genotypes (El-MYC,E l-MYC/BCR
HEL, and El-
MYC/BCR
HEL/sHEL).
We conclude that tumors of El-MYC/BCR
HEL,E l-MYC/
BCR
HEL/sHEL and MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL
mice arose from a limited number of B cell clones. The
multiclonality of the tumors sets them apart from their
ostensible human counterparts, which are typically mono-
clonal [31]. We attribute this clonal dominance to selection of
clones in which even further tumorigenic events have
occurred (see Discussion).
Antigen Dependence of Tumors
We wanted to explore the speciﬁc contribution of antigen-
dependent signaling to lymphoid transformation in the El-
MYC/BCR
HEL/sHEL tumors. As a ﬁrst approach, we asked
whether the exogenous antigen (HEL) could alter phenotypi-
cally normal MMTV-tTA/TRE-MYC/BCR
HEL cells to resemble
the tumor cells of
El-MYC/BCR
HEL/sHEL and MMTV-rtTA/TRE-MYC/
BCR
HEL/sHEL mice. Cells were taken from 4–6-wk-old
MMTV-rtTA/TRE-MYC/BCR
HEL mice that had been fed
Figure 3. Histological Analysis of Tumors
Tissues were sectioned, stained with hematoxylin and eosin, and microscopic images obtained as described in Methods. Magnification was 10X for (A–
E), 100X for (F–J).
(A and F) Spleen from a normal wild-type mouse.
(B and G) Lymph node tumor from an El-MYC mouse.
(C and H) Spleen tumor from an El-MYC/BCR
HEL mouse.
(D and I) Spleen tumor from an El-MYC/BCR
HEL/sHEL mouse.
(E and J) Jaw tumor from an MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL mouse.
doi:10.1371/journal.pbio.0060152.g003
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Contributions of BCR to B Cell Lymphomagenesisdoxycycline-containing food since birth in order to suppress
expression of the MYC transgene (Figure S3). The donor
animals appeared clinically normal, and had normal numbers
of cells in their lymph nodes and spleen (unpublished data).
The donor cells were tracked throughout the experiment by
ﬂow cytometric analysis for a B cell marker (B220) and the
BCR
HEL. Donor cells were transferred to either C57/BL6 mice
or age and sex matched mice carrying only the transgene for
sHEL. The recipient mice were not treated with doxycycline
to allow activation of the MYC transgene in the donor cells. In
the absence of sHEL, the number of donor cells detectable in
recipient mice did not change (Figure 4A) and the mice
remained healthy. In contrast, the number of donor cells in
sHEL recipients rose continuously over time (Figure 4A) until
the mice developed overt tumors, 8–12 d after receiving the
transplanted cells, and eventually died within 28–30 d.
In order to test the durability of the requirement for
antigen, we harvested tumor cells that had arisen after the
initial transplantation of MMTV-rtTA/TRE-MYC/BCR
HEL
cells into sHEL mice and introduced these into either wild-
type or a second set of sHEL mice that were not treated with
doxycycline. Donor cells again ampliﬁed rapidly in the sHEL
mice, but not in wild-type recipients (Figure 4C). Tumors
resulted in death of the recipient mice within 12–16 d, a
latency appreciably shorter than that observed after the
preceding transplantation (28–30 d).
The ﬂow cytometric proﬁle of the donor cells changed after
their encounter with antigen. The donor cells expressed
B220, BCR
HEL, CD19, CD21, and CD23, but did not express
CD69 or B7–2 on their surface. The cells that resulted from
the expansion following antigenic stimulation in vivo showed
a loss of CD23 expression and high levels of CD69 and B7–2
expression (unpublished data). The same phenotype was
observed with the cells that had expanded following the
second transplantation into sHEL recipient mice. This
phenotype is typical of antigen-activated B cells. In addition,
it is similar to what we initially observed in the cells from
tumors that arose in the El-MYC/BCR
HEL/sHEL mice and,
thus, also resembles the phenotype of BL (Table 1). We
conclude that the appearance and expansion of HEL-speciﬁc,
BL-like tumor cells in the recipient mice were dependent on
stimulation by the cognate antigen.
In contrast to the preceding ﬁndings, tumor cells obtained
T
a
b
l
e
1
.
C
e
l
l
-
S
u
r
f
a
c
e
M
a
r
k
e
r
s
o
f
B
C
L
s
C
e
l
l
S
u
r
f
a
c
e
M
a
r
k
e
r
E
l
-
M
Y
C
E
l
-
M
Y
C
/
B
C
R
H
E
L
E
l
-
M
Y
C
/
B
C
R
H
E
L
/
s
H
E
L
M
M
T
V
-
r
t
T
A
/
T
R
E
-
M
Y
C
/
B
C
R
H
E
L
M
M
T
V
-
r
t
T
A
/
T
R
E
-
M
Y
C
/
B
C
R
H
E
L
/
S
H
E
L
E
l
-
M
Y
C
/
V
D
J
k
i
/
L
t
-
t
g
/
s
H
E
L
H
u
m
a
n
B
L
H
u
m
a
n
B
-
C
L
L
B
2
2
0
þ
þ
þ
þ
þ
þ
þ
þ
C
D
1
9
þ
þ
þ
þ
þ
þ
þ
þ
C
D
5
þ
-
-
-
-
-
-
þ
C
D
2
1
-
þ
þ
þ
þ
þ
þ
þ
C
D
2
3
-
þ
-
þ
-
-
-
þ
P
N
A
-
-
þ
-
þ
þ
N
D
a
-
B
7
–
2
-
-
þ
-
þ
þ
þ
-
C
D
6
9
-
-
þ
-
þ
þ
N
D
a
-
I
g
M
-
þ
þ
þ
þ
þ
þ
þ
B
C
R
H
E
L
,
b
-
þ
þ
-
þ
þ
N
A
c
N
A
c
S
i
n
g
l
e
-
c
e
l
l
s
u
s
p
e
n
s
i
o
n
s
w
e
r
e
g
e
n
e
r
a
t
e
d
f
r
o
m
l
y
m
p
h
n
o
d
e
s
,
s
p
l
e
e
n
s
,
o
r
b
o
n
e
m
a
r
r
o
w
f
r
o
m
m
i
c
e
w
i
t
h
t
h
e
i
n
d
i
c
a
t
e
d
g
e
n
o
t
y
p
e
s
,
s
t
a
i
n
e
d
w
i
t
h
t
h
e
i
n
d
i
c
a
t
e
d
m
a
r
k
e
r
s
,
a
n
d
a
n
a
l
y
z
e
d
b
y
f
l
o
w
c
y
t
o
m
e
t
r
y
.
A
l
l
s
t
a
i
n
s
w
e
r
e
c
o
m
p
a
r
e
d
t
o
h
e
a
l
t
h
y
w
i
l
d
-
t
y
p
e
m
i
c
e
,
a
n
d
t
h
e
t
u
m
o
r
-
b
e
a
r
i
n
g
m
i
c
e
w
e
r
e
h
a
r
v
e
s
t
e
d
a
t
a
t
i
m
e
c
o
n
s
i
s
t
e
n
t
w
i
t
h
t
h
e
o
n
s
e
t
o
f
d
i
s
e
a
s
e
p
r
e
s
e
n
t
e
d
i
n
F
i
g
u
r
e
1
A
.
W
e
d
e
f
i
n
e
t
h
e
e
x
p
r
e
s
s
i
o
n
o
f
a
c
e
l
l
-
s
u
r
f
a
c
e
m
a
r
k
e
r
a
s
p
o
s
i
t
i
v
e
(
þ
)
w
h
e
n
t
h
e
m
e
a
n
f
l
u
o
r
e
s
c
e
n
c
e
i
n
m
e
a
s
u
r
e
m
e
n
t
s
w
i
t
h
f
l
o
w
c
y
t
o
m
e
t
e
r
y
i
s
h
i
g
h
e
r
t
h
a
n
3
0
(
F
i
g
u
r
e
S
1
)
.
S
u
r
f
a
c
e
p
h
e
n
o
t
y
p
e
s
o
f
m
u
r
i
n
e
t
u
m
o
r
s
a
r
e
b
a
s
e
d
o
n
c
o
n
s
i
s
t
e
n
t
r
e
s
u
l
t
s
o
b
t
a
i
n
e
d
f
r
o
m
a
t
l
e
a
s
t
e
i
g
h
t
i
n
d
e
p
e
n
d
e
n
t
p
r
i
m
a
r
y
t
u
m
o
r
s
p
e
r
g
e
n
o
t
y
p
e
.
a
N
o
t
d
e
t
e
r
m
i
n
e
d
b
T
h
e
l
e
v
e
l
s
o
f
B
C
R
H
E
L
p
r
o
t
e
i
n
p
r
e
s
e
n
t
o
n
t
h
e
s
u
r
f
a
c
e
o
f
t
h
e
s
e
c
e
l
l
s
w
a
s
d
e
t
e
r
m
i
n
e
d
b
y
m
e
a
s
u
r
e
m
e
n
t
o
f
H
E
L
-
p
r
o
t
e
i
n
b
i
n
d
i
n
g
.
T
h
e
c
e
l
l
s
w
e
r
e
i
n
c
u
b
a
t
e
d
w
i
t
h
H
E
L
(
1
m
g
/
m
l
)
a
n
d
s
u
b
s
e
q
u
e
n
t
l
y
w
i
t
h
a
n
a
n
t
i
-
H
E
L
a
n
t
i
b
o
d
y
(
H
y
9
)
.
c
N
o
t
a
p
p
l
i
c
a
b
l
e
.
T
h
i
s
a
n
t
i
g
e
n
i
c
s
p
e
c
i
f
i
c
i
t
y
w
a
s
i
n
t
r
o
d
u
c
e
d
e
x
p
e
r
i
m
e
n
t
a
l
l
y
i
n
t
o
t
h
e
m
o
u
s
e
m
o
d
e
l
s
.
I
t
i
s
n
o
t
a
f
e
a
t
u
r
e
o
f
h
u
m
a
n
B
L
o
r
B
-
C
L
L
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
b
i
o
.
0
0
6
0
1
5
2
.
t
0
0
1
Table 2. The Clonality of Tumors
Mouse Individual
Clones
a
Germ Line
Configuration
C57/BL-6 (wild type) TNTC
b þ
C57/BL-6 (lpr/lpr) TNTC
b þ
El-MYC 1–2 0
El-MYC/BCR
HEL 10–15 0
El-MYC/BCR
HEL/Shel 20–40 0
MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL (jaw) 15–30 0
a Individual clones were represented by clearly distinguishable bands that migrated on an
agarose gel differently from the germ line configurations, and appeared only when a
specific combination of primers for a VH and a JH segment was used for the PCR reaction
(Figure S2). The range of bands presented was derived from the analysis of cells obtained
from four independent primary tumors per genotype.
b Too numerous to count. This refers to polyclonal populations, which yielded a smear in
an agarose gel, as opposed to clearly distinguishable individual bands (see Figure S2).
doi:10.1371/journal.pbio.0060152.t002
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HEL/sHEL mice or MMTV-rtTA/TRE-MYC/
BCR
HEL/sHEL mice would grow into lethal tumors when
transplanted into recipient mice in the absence of HEL
antigen (Figure 4A, 4C, and 4F). We postulated that this
seeming independence of antigen was due to the intrinsic
production of antigen by the tumor cells themselves, as would
be expected from the genotype of the cells. That proved to be
the case. We were able to detect HEL transcripts and HEL
protein in cells obtained from either a primary El-MYC/
BCR
HEL/sHEL tumor or an MMTV-TRE-MYC/BCR
HEL/sHEL
tumor, but not in cells obtained from either El-MYC or El-
MYC/BCR
HEL tumors (unpublished data). Similarly, we found
HEL protein in tumors that arose following transplantation
of cells from a primary El-MYC/BCR
HEL/sHEL tumor. We
conclude that the murine BL cells are in fact antigen-
dependent, but can be sustained by either autocrine or
paracrine stimulus.
Mature B Cell Tumors Require Continuous Signaling from
the BCR
To further test the role of antigen stimulation in the
genesis of the B-CLL– and BL-like tumors, we disrupted the
molecular machinery that generates and transmits signals
from the BCR. By transduction of suitable interfering RNAs
into established tumor cells, we were able to suppress the
expression of the Iga and Igb signaling chains of the BCR. We
have previously shown that these shRNA sequences targeting
Iga and Igb lead to substantial reduction in the levels of Iga
Figure 4. Establishment and Maintenance of Murine BL by Antigenic Stimulus and MYC Overexpression
(A and B) Primary transplants. Spleen and lymph node cells were harvested from an MMTV-rtTA/TRE-MYC/BCR
HEL mouse at 4 wk of age. Cells from
spleen and lymph nodes were pooled at a 1:1 ratio, and 10
6 cells were introduced into either syngeneic wild-type mice (empty circles) or sHEL
transgenic mice (filled circles) by intravenous injection. Cohorts of mice were either kept on regular food (A), or on doxycycline-containing food (B).
Tissues were collected at indicated time points from spleens and analyzed for total number of cells. Samples taken from wild-type mice were analyzed
at the same times (empty squares).
(C and D) Secondary transplants. Cells were collected from tumors of spleens and lymph nodes represented in (A), 16 d after their initiation by
transplantation. Cells from spleen and lymph nodes were pooled at a 1:1 ratio, and 10
5 cells were introduced into either wild-type recipients (empty
circles) or sHEL transgenic mice (filled circles) by intravenous injection. The empty squares represent wild-type, unmanipulated mice that were analyzed
in parallel with the experimental groups. Cohorts of mice were either kept on regular food (C), or on doxycycline-containing food (D). Cells were
collected from spleens at the indicated times after the transplantation and analyzed as in (A and B).
(E and F) BCLs regress after MYC overexpression is extinguished. (E) A cohort of mice similar to those described in (A) was allowed to develop externally
visible lymphadenopathy. 16 d later, those mice were switched to a doxycycline-containing diet. The empty circles represent wild-type recipient mice
that received transplants of MMTV-rtTA/TRE-MYC/BCR
HEL cells, the filled circles represent sHEL transgenic mice that received transplants of those cells,
the empty squares represent wild-type, unmanipulated mice that were analyzed in these experiments in parallel with the experimental mice. Cells were
collected from spleens at the indicated times after the transplantation and analyzed as in (A and B). (F) MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL mice were
allowed to develop tumors spontaneously, as a result of transgene function. Approximately 40 d later, mice with externally apparent lymphadenopathy
were given doxycycline containing food (day 0 in figure). Cells were collected from lymph nodes at the indicated times after exposure of the mice to
doxycycline and analyzed as in (A and B). The empty circles represent MMTV-rtTA/TRE-MYC/BCR
HEL mice that were never exposed to docycycline, the
filled circles represent MMTV-rtTA/TRE-MYC/BCR
HEL mice that were given doxycycline-containing food after they developed externally apparent
lymphadenopathy, the empty squares represent wild-type, unmanipulated mice that were analyzed in parallel with the experimental mice.
doi:10.1371/journal.pbio.0060152.g004
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observed that shRNAs directed at either Iga or Igb
individually caused a decrease in the levels of surface IgM
in transduced B cells. Importantly, the expression of Iga and
Igb on the cell surface modulates the surface expression of
IgH and IgL, the antigen-speciﬁc components of the BCR.
The vector used for transduction was a lentivirus that has
been previously described [34]. The viruses tested in vitro and
in vivo were the parental vector encoding either GFP
(pLL3.7) or Thy1.1 (pLL3.77) as a reporter gene, and variants
encoding both a reporter gene and shRNAs for either Iga,
Igb, or ﬁreﬂy luciferase, the last as a negative control.
Transduction was performed with tumor cells isolated from
either El-MYC/BCR
HEL mice or El-MYC/BCR
HEL/sHEL mice.
The rates of transduction varied between 5%–50% of the
tumor cells (Figure 5A). The cells were then maintained in
Figure 5. The Maintenance of Tumors Derived from El-MYC/BCR
HEL and El-MYC/BCR
HEL/sHEL Mice Depends on the Continued Expression of Iga or Igb
(A) Cell lines were generated from either El-MYC/BCR
HEL tumors and designated as DBL114, or from El-MYC/BCR
HEL/sHEL tumors and designated TBL-1.
These cell lines uniformly express B220 and IgM on their surface. To determine whether the shRNA sequences targeting Iga were able to knock down
their target protein, we measured the levels of IgM expressed on the surface of DBL-114 cells that were transduced with lentiviral constructs that
encode a reporter gene (GFP). The expression of IgM on the surface is co-modulated with Iga expression, hence the loss of Iga should reduce the levels
of surface IgM. The panels represent the flow cytometric profile of the DBL-114 cells that had been transduced with the parental virus (pLL3.7), or a
variant that encodes an shRNA specific for firefly luciferase, as a negative control, or two variants of pLL3.7 that encode different shRNAs specific for Iga.
The GFP-positive cells in the panels that contained shRNAs specific for Iga showed a loss of surface IgM expression. This is not the case for the GFP-
negative fraction of the same cell populations. Similar results were obtained in TBL-1 cells (unpublished data).
(B) The shRNA-mediated knock-down of Iga or Igb in cells obtained from either El-MYC/BCR
HEL or El-MYC/BCR
HEL/sHEL tumors confers a competitive
disadvantage on those cells in vitro, compared to their nontransduced counterparts. Single-cell suspensions were generated from the respective
tumors, and used for lentiviral transductions. The cells were maintained in cultured and assayed for GFP expression, by flow cytometry every 24 h. The
data for the GFPþ fraction in the population of cells harboring a lentivirus encoding and shRNA was divided by the fraction of GFPþ cells in the
population of cells that was transduced with the parental vector, in order to standardize the values and examine the rates of change from the starting
level of GFPþcells, as previously reported [104]. The cells that were transduced with lentiviruses encoding shRNAs specific for either Iga or Igb exhibited
a significant competitive disadvantage when compared to the cells harboring lentiviruses encoding shRNAs specific for firefly luciferase. All wells were
set up in triplicates. The graphs represent data from one experiment, representative of eight independent experiments.
(C) In vivo validation of the effects of Iga-specific shRNAs on the maintenance of El-MYC/BCR
HEL tumors. Cells were obtained from El-MYC/BCR
HEL
tumors, and transduced in vitro with pLL3.77-sh.luciferase (uses thy1.1 as a reporter gene) or pLL3.7-sh.Iga.1 (uses GFP as a reporter gene). The different
cell populations were then mixed in order to generate mixtures of cells that contained an approximately equal fraction of cells that harbored the
control lentivirus (pLL3.77.sh.luciferase) and the experimental lentivirus (pLL3.7.sh.Iga). The mixtures of cells were transplanted into cohorts of Rag-1
–/–
mice. The mice were observed daily until they exhibited externally evident signs of lymphoma, and the organs were harvested. The graphs represent
the fraction of cells in the tumorous lymph nodes that retained expression of either thy1.1 (for the control lentivirus), or GFP (for the Iga-specific
lentivirus. These results confirm the requirement for Iga expression in the maintenance of the murine BCLs.
doi:10.1371/journal.pbio.0060152.g005
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expression.
We observed that for both El-MYC/BCR
HEL and El-MYC/
BCR
HEL/sHEL tumors, the percentage of cells transduced with
either the parental lentivirus, or the variant that encoded
shRNA speciﬁc to ﬁreﬂy luciferase, did not change appreci-
ably during a 14 day period (Figure 5B). In contrast, each of
the cultures that was transduced with a lentiviral variant that
encoded shRNAs speciﬁc to either Iga or Igb displayed a
signiﬁcant decrease in the frequency of the cells expressing
the reporter gene (Figure 5B). The same pattern was observed
with two independent shRNAs for each of Iga and Igb. This in
vitro competition assay suggested that loss of signaling from
the BCR placed the tumor cells at a signiﬁcant disadvantage
when compared to their counterparts that had retained
normal signaling from the BCR. In addition, these results
demonstrate that the signaling components of the BCR are
required for tumors that depend on autogenous signaling by
the BCR-derived signals as well as for those that rely on the
cognate-antigen–induced BCR signals.
To verify these observations in vivo, we isolated tumor cells
from El-MYC/BCR
HEL mice, and transduced them as de-
scribed above. We then transplanted the transduced tumor
cells into Rag-1
–/– mice, to evaluate tumor ﬁtness in the
absence of any T cell responses to the reporter genes. In this
instance, we mixed tumor cells that had been transduced with
pLL3.77 (providing thy1.1 as a reporter) encoding an shRNA
to ﬁreﬂy luciferase with tumor cells transduced with pLL3.7
(providing GFP as a reporter) encoding shRNAs speciﬁc to
either Iga or Igb. This would provide internal controls for
e a c ho ft h em i c ew et r a n s p l a n t e di nt h ec o h o r t .W e
euthanized the mice 21 days after transplantation, when they
developed external signs associated with lymphoma (scruffy
fur, hunched posture, lymphadenopathy, dehydration, la-
bored breathing, and an ascending hind limb paralysis). The
lymph nodes and spleens were collected and used to generate
single-cell suspensions. The cells were then stained and
analyzed by ﬂow cytometry.
Tumor cells transduced with either pLL3.7-sh.Iga or
pLL3.7-shIgb failed to expand in vivo (Figure 5C), mirroring
the results obtained in vitro. In contrast, the nontransduced
cells, or the cells transduced with pLL3.77-sh.Luc, expanded
in vivo and gave rise to the resulting malignancies. In
addition, the genetic disruption of Syk, a key membrane-
proximal element of the BCR signal, also conferred a
signiﬁcant competitive disadvantage to established BCL cells
in a manner analogous to what we present here with Iga or
Igb (RMY and YR, unpublished results). These results show
that for both tumor types, the acute loss of the signaling
components of the BCR complex resulted in a severe
competitive disadvantage in vivo, suggesting that these two
types of tumors are dependent upon continuous signaling
from the BCR.
The Response of Tumors to Immunosuppressants
The apparent contribution of BCR signaling to the
development of murine lymphomas prompted us to explore
the effect of immunosuppressants on the various mouse
models. We used cyclosporin A, FK506, and rapamycin to
treat well advanced tumors that had been initiated by
transplantation. We compared the effects of these agents to
that of cyclophosphamide, an agent commonly used to treat
human BL [35].
We transplanted 10
6 cells obtained from tumor-bearing
spleen or lymph nodes into cohorts of 4–10 mice. The
recipient mice were held for observation until they developed
externally obvious lymphadenopathy (approximately 100 d
for the El-MYC tumors, 58 d for the El-MYC/BCR
HEL tumors,
21 d for the El-MYC/BCR
HEL/sHEL tumors, and 14 d for the
MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL tumors). The tumor
bearing and control wild-type mice were then treated daily
for 7 d with intravenous injections of the various drugs. Mice
were either euthanized 24 h after the last injection of drug, or
held indeﬁnitely to ascertain duration of survival. The
analysis of tumor burden was performed with cells obtained
from lymph nodes and spleens.
The El-MYC tumors did not respond to any of the
immunosuppressive drugs we tested (Figure 6A and 6E).
Disease progressed at the same rate in treated and untreated
mice. Histological examination of the affected organs also
revealed no evidence of therapeutic response (unpublished
data). In contrast, the transplanted El-MYC tumors showed a
strong response to cyclophosphamide, as previously de-
scribed [36]. Treatment with cyclophosphamide elicited
tumor regression in all animals, but also caused a more
general cytotoxicity, manifested as a reduction in T cells,
myeloid cells, and nontransgenic B cells (unpublished data).
Similar toxicity from cyclophosphamide was also observed in
wild-type mice.
The tumors derived from the El-MYC/BCR
HEL mice
responded to cyclophosphamide and cyclosporin, but not to
either FK506 or rapamycin (Figure 6B and 6F). In contrast,
the tumors from El-MYC/BCR
HEL/sHEL mice, as well as
tumors from the jaws of MMTV-rtTA/TRE-MYC/BCR
HEL/
sHEL mice, responded to both cyclophosphamide and all
three of the immunosuppressants tested (Figure 6C, 6D, 6G,
6H). The different sensitivities of the tumors derived from
El-MYC/BCR
HEL mice and those derived from either El-MYC/
BCR
HEL/sHEL or MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL mice
suggests that the constitutive and cognate-antigen–derived
BCR signals may be qualitatively distinct.
Remissions of El-MYC/BCR
HEL/sHEL tumors persisted for
at least 5 mo, following a 7-d course of treatment with
immunosuppressants (Figure 6I and unpublished data). In
contrast, the animals treated with cyclophosphamide entered
a brief remission, but still died more rapidly than did
untreated, tumor-bearing mice (Figure 6I and unpublished
data), apparently consequent to the toxicity described above.
In summary, the response of the various model tumors
varied consistently with the genotypes of the mice. B cell
tumors that arose from the combined effects of MYC and
antigen stimulus responded uniformly to three distinctive
immunosuppressants, whereas only one of the three agents
was effective against tumors elicited by MYC and a con-
stitutive BCR (For data demonstrating the post-GC nature of
antigen-stimulated tumors, see Figure S4). Since the El-MYC
tumors do not express BCR on their surface, they were
presumably devoid of any apparent stimulus from the
receptor, and were resistant to all the immunosuppressants
tested. These results are in accord with two of our hypotheses:
that tumorigenesis can be inﬂuenced by signals from the
BCR, and that the signals generated by constitutive receptor
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receptor (see Discussion).
MYC Dependence of Tumors
We also explored whether the murine BL-like tumors were
dependent on the continuous overexpression of MYC. To test
this issue on established tumors, we allowed MMTV-rtTA/
TRE-MYC/BCR
HEL/sHEL mice to develop tumors in the
absence of doxycycline. The mice were then given doxycy-
cline-containing food in order to suppress the expression of
the MYC transgene (Figure S3). The tumors quickly regressed
(Figure 4F and unpublished data).
The establishment and maintenance of the BL-like tumors
that arose following transplantation of MMTV-rtTA/TRE-
Figure 6. Suppression of Tumor Growth by Pharmacological Agents
Tumor cells were harvested from lymph nodes and spleens and transplanted as described in Methods. The recipient mice were held until tumors
became clinically apparent. Tumor recipient (open bars) and wild type (filled bars) mice then received daily injections of the indicated drugs for 7 d of
either cyclosporine A (csa), FK506, rapamycin (rap), or cyclophosphamide (cyph). For (A–H), the mice were euthanized 24 h after the last injection of
drug, and lymph nodes were harvested for analysis of either total number of cells (A–D) (expressed in single units representing 10
6 cells each) or surface
markers of donor cells (E–H). For (I), the mice were observed over a span of 100 da and deaths recorded, as shown.
(A and E) El-MYC tumors.
(B and F) El-MYC/BCR
HEL tumors.
(C and G) El-MYC/BCR
HEL/sHEL tumors.
(D and H) MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL tumors.
(I) Survival of animals bearing El-MYC/BCR
HEL/sHEL tumors. The statistical significance of the differences observed in the kinetics of mortality between
the tumor-bearing mice that were either untreated, or treated transiently with cyclophosphamide is 0.01. The statistical significance of the difference in
the mortality curves observed between those two groups and the tumor-bearing mice treated with either of the three immunosuppressant drugs is p ,
0.001.
doi:10.1371/journal.pbio.0060152.g006
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HEL cells into sHEL mice was also dependent upon
the overexpression of MYC. This conclusion was based on
several ﬁndings. First, the transplantation of cells MMTV-
rtTA/TRE-MYC/BCR
HEL could not give rise to tumors if the
transplanted cells were prohibited from expressing their MYC
transgene by administration of doxycycline to the recipient
mice (Figure 4B). Second, tumor cells that had arisen from
the transplantation of MMTV-rtTA/TRE-MYC/BCR
HEL cells
could not be further passaged in the absence of overex-
pressed MYC (Figure 4D). And third, tumors that arose
following transplantation of MMTV-rtTA/TRE-MYC/BCR
HEL
cells would regress once expression of the MYC transgene was
extinguished with doxycycline (Figure 4E). We conclude that
the development and maintenance of the BL-like tumors
requires continuous stimulation by MYC.
Discussion
Previous observations have raised the possibility that
expression of a BCR can contribute to the genesis of
lymphomas (reviewed in [3]). We have used transgenic mice
to explore this possibility. Our results demonstrated that both
the constitutive and antigen-stimulated states of the BCR can
cooperate with overexpression of the proto-oncogene MYC in
the genesis of BCLs. The types of B cell tumors produced in
the two instances differ appreciably, with the former
resembling a subset of human B-CLL, the latter resembling
human BL. This work provides a direct demonstration that
signaling from the BCR can contribute to lymphomagenesis.
The mouse models described here should be useful for
further study of tumorigenesis in the B cell lineage, and for
preclinical testing of therapeutics.
The BCR Can Contribute to Lymphomagenesis in Both the
Absence and Presence of Cognate Antigen
Previous work has shown that overexpression of MYC in the
B cell lineage can give rise to lymphomas in mice (reviewed in
[20]). We have now found that the BCR can both accelerate
tumorigenesis by MYC and alter the nature of the resulting
tumors. The acceleration is greater when the BCR is
stimulated by antigen than when it is not, and the resulting
tumors differ in their clinical behavior, anatomical presenta-
tion, histopathology, and surface phenotype. In addition, the
two sorts of tumors respond differently to a trio of
immunosuppressants, each of which can probably act on
distinct signaling pathways activated by antigen receptor [37–
39]. We attribute these differences among the tumors to the
fact that the BCR can apparently generate at least two forms
of signals—one produced by the binding of the cognate
antigen, the other an ‘‘autogenous’’ signal generated by the
ostensibly unstimulated receptor [5]. Our results sustain the
view that the two forms of signals are different, suggest that
this difference affects the nature of the tumors produced by
MYC, and provide direct evidence that each of the two forms
of signaling can contribute to lymphomagenesis—a notion
that has heretofore been based solely on correlative data.
The biochemical nature of the constitutive signal derived
from the BCR remains to be determined. Our genetic studies
involving the disruption of Iga or Igb in established tumors
suggests that both of those signaling chains are required for
constitutive and cognate antigen triggered signals. The results
we obtained showing differential sensitivity to cyclosporine
A, FK506, and rapamycin in murine BL- and B-CLL–like
tumors suggest that the two signals derived from the BCR
involve the activation of different transduction pathways. The
tumor models we have developed may also enable us to
dissect the molecular basis of constitutive BCR signaling in
the context of B cell development and neoplasia.
Signaling by the antigen-stimulated BCR has been studied
in great depth [40]. It is known to mediate B cell proliferation
and could contribute to tumorigenesis if sustained inap-
propriately. We have shown here that antigen-stimulated
signaling from the BCR can cooperate with the oncogene
MYC to produce tumors that remain dependent upon antigen
and that resemble BL of humans. Yan et al. recently reported
that autoantigenic drive may contribute to the genesis of a
tumor resembling CD5þ B-CLL in mice expressing a trans-
gene of TCL1 [41]. These authors suggested a link to BCR
signaling, based on their analysis of endogenous BCR usage.
The presence of repeated patterns may be suggestive of
conserved antigenic stimulation, but is not deﬁnitive.
Whether a common speciﬁcity is a foreign or self-antigen is
also unclear from the pattern of BCR usage. A second tcl-1
transgenic mouse presented with a tumor phenotype of large
BCLs (BL, diffuse large B-cell lymphoma (DLBCL)). Those
tumors were all CD5
–, suggesting an inherent difference the
two transgenic mouse strains that overexpress tcl-1 in both
mature B-cell compartments [42]. A Bcl-6 transgenic mouse
has also been reported to yield DLBCL-like tumors in mice
that presented with a post-GC phenotype [43]. Importantly,
our work involves the overexpression of MYC in the context
of autoreactive B cells. The overexpression of MYC is the
characteristic genetic lesion in BL, such that these mouse
models are the most germane to the mechanisms that give
rise to BL.
Two recent reports have also implicated autoantigenic
stimulation of B cells either in the genesis of a lymphoma that
occurs in mice expressing a transgene for the TCL1 gene, and
that resembles human B-CLL [41], or in the instance of
DLBCL-like tumors that arose in Bcl-6 transgenic mice [43].
Subsequent analysis of the DLBCL-like tumors that develop
in the Bcl-6 transgenic mice demonstrated a need for AID
expression for the genesis of those post-GC B cell malig-
nancies [44]. Our work provides a direct demonstration that
autoantigenic stimulation can contribute to lymphomagene-
sis. The comparison of the constitutive and cognate-antigen–
stimulated BCR is unique in the context of tumorigenesis
models. In fact, the models we have developed represent the
closest genotypic and phenotypic approximation to human
BL.
In contrast, the autogenous form of BCR signaling remains
something of an enigma [5]. Both the origin and the effectors
of this signal are less understood than antigen-dependent
BCR signals, but the signal appears to be important in B cell
development and survival of mature, naı ¨ve B cells, and is
implicated in homeostatic control over the size of the
lymphoid compartment between immune responses [4,6]. It
is not clear if the same signal is responsible for these several
functions; alternatively, the responsible signals might differ
from one another either quantitatively or qualitatively. In the
present work, an autogenous signal from a mature BCR
cooperated with MYC to produce a lymphoma that was
distinctively different from the tumor produced when the
same BCR was subjected to sustained antigenic stimulus. This
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stimulated signaling from the BCR must differ in some way.
In a previous report, introduction of a transgene for the
human IgH chain into El-MYC mice delayed the onset of
tumors and sometimes changed the involved cells to the
myeloid and T cell lineages [45]. Using a different strain of
El-MYC mice [20], we found that a murine BCR accelerated
tumorigenesis and did not change the affected lineage. In
addition, we conﬁrmed our observations with a second strain
of mice that overexpress MYC in the B cell lineage (MMTV-
rtTA/TRE-MYC). We suggest that the different outcomes in
the present and previous work may be due to the use of
substantially different transgenes, but we have not explored
the matter further, because it appears not to bear on our
conclusions.
The tumors that arose in the MMTV-rtTA/TRE-MYC/
BCR
HEL/sHEL mice displayed sustained dependence upon
both the activity of the MYC transgene and the stimulus to
tumor cells provided by a cognate autoantigen. These
ﬁndings are in accord with recent reports of diverse mouse
models in which the survival and growth of tumors remain
dependent upon the genetic lesion that initiated tumori-
genesis (for examples, see [46–49]; see [50] for a review). In the
present instance, we have demonstrated dependence upon
two distinctive tumorigenic inﬂuences. MYC initiates and is
also involved in some level in the maintenance of tumors,
whereas antigenic stimulus may sustain cellular proliferation,
promote cell survival, or affect cellular differentiation.
Moreover, MYC can facilitate the effect of autoantigen by
breaking immune tolerance in B cells ([51], and see below).
The future design of targeted therapies for cancer will
probably beneﬁt from the elucidation of such interactions
among the steps in tumor progression.
Immune Tolerance May Have a Role in Lymphomagenesis
We initiated the current work in order to explore the role
of antigenic stimulus in the genesis of lymphomas. We used a
model in which the bulk of B cells are programmed to
respond to a single antigen (HEL), which in turn is also
provided as a neo-autoantigen by a transgene. As originally
described, mice bearing these two transgenes are anergic for
the transgenic autoantigen [25]. So the discovery that the
HEL autoantigen could cooperate in tumorigenesis seemed
counterintuitive. As reported by us elsewhere [51], however,
overexpression of transgenic MYC apparently reversibly
breaks tolerance in these mice and allows B cells to respond
to the HEL autoantigen. Accordingly, the tumors are
composed of mature, activated B cells with high-afﬁnity
receptors for HEL.
We attribute these ﬁndings to the fact that in both B and T
cells, the abundant expression of MYC can serve as a
surrogate for cytokines [51–55]. It has been shown previously
that cytokines can override B cell tolerance [56]. Whatever its
mechanism, the breach of tolerance by MYC in the El-MYC/
BCR
HEL/sHEL transgenic mice permits a strong autoantigenic
drive of B cell proliferation, and this in turn apparently
modiﬁes tumorigenesis by the oncogene.
There is circumstantial evidence that associates broken
tolerance with lymphomagenesis in humans. First, the
incidence of lymphoid neoplasms is increased in various
autoimmune syndromes [57]. For example, individuals with
Sjo ¨rgen syndrome display a nearly 50-fold increase in the
incidence of either diffuse large BCL or follicular BCL [58].
Second, individuals with BL and other forms of non-Hodgkin
lymphoma (NHL) frequently have high levels of autoanti-
bodies in their sera [59–64] and develop autoimmune
hemolytic anemia [65,66]. In addition, the sequences of the
Ig receptors expressed by cells of NHL have been shown to
contain mutations that may have arisen during a GC reaction
[67]. These mutations may alter receptor speciﬁcity, render-
ing the cells autoreactive. A history of hypermutation in these
tumors is also manifested by a high frequency of mutations in
alleles of MYC that have not been translocated [68]. Given the
role of MYC in the mouse tumors described here, it might be
proﬁtable to explore the effect of other oncogenes on
immune tolerance.
A Mouse Model for BL
We have described two mouse models that develop a
lymphoma with a close resemblance to human BL. The
similarities include anatomical presentation and other
clinical manifestations, histological appearance, and immu-
nophenotype. A particularly striking ﬁnding was the unilat-
eral occurrence of jaw tumors in the MMTV-rtTA/TRE-MYC/
BCR
HEL/sHEL mice. This manifestation is characteristic of
African BL [69], but remains unexplained in both the human
and murine setting. In addition, we have shown that the BL-
like tumors are composed of cells that have undergone a GC
reaction. The evidence supporting this notion includes:
expression of cell surface markers that are consistent with a
post-GC cell; the presence of class switched immunoglobulins
speciﬁc to the model autoantigen, HEL; the presence of point
mutations in the BCR that are likely the result of somatic
mutation that occurs during the GC reaction; and the
detection of high levels of mRNA for two GC-associated
genes, Bcl-6 and AID. This is the most complete set of
parameters yet used to deﬁne a mouse model of BL.
Several previous reports have described experimental
approaches that might have produced mouse models of BL
[20,47,70–73]. Only one of these attempts, however, produced
a tumor with substantive resemblances to BL [72]. That model
used the control of the Igk-MYC promoter and enhancer
elements to express a mutant form of MYC that is found in
human NHL. No provision was made for deliberate antigenic
stimulation of B cells, but the tumor cells did show evidence
of immune selection, in the form of point mutations in the Ig
loci. In addition, we have demonstrated the GC origin of the
BL tumors in our mouse model, whereas this was not the case
for the lymphomas that developed in Igk-MYC mice [72].
These ﬁndings prompted the authors to invoke stimulus by an
unidentiﬁed antigen in the genesis of the murine tumors. Our
work reconstructs such stimulus with a clonal BCR and
cognate neo-autoantigen, and demonstrates a contribution of
the stimulus to tumorigenesis.
BL appears in two major forms: endemic and sporadic. The
endemic form is found mainly in Africa and is characterized
by infection with Epstein-Barr virus (EBV) [74,75]. In contrast,
an association with EBV infection is found in only about 20%
of sporadic BL, but chronic infection with another, as yet
unidentiﬁed microbe might well ﬁgure in the remainder.
Viral infection plays no role in the mouse models of BL
described here. We presume that the need for such infection
has been circumvented by overexpression of the MYC
transgene, which serves as a surrogate for the translocations
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subsequent to initiation of tumorigenesis by EBV or another
agent [76].
With few exceptions, the tumor cells of BL have been
described as monoclonal [77–80]. In contrast, the tumor cells
in the two animal models for BL described here are
multiclonal. How might we explain this distinction? The
human tumor presumably arises from a series of rare events,
each ampliﬁed by clonal selection ([81]; reviewed in [82]). The
cumulative rarity in this sequence of events dictates that the
eventual tumor is likely to be the product of a single clonal
lineage. In contrast, the experimental model described here
provides at least two potentially tumorigenic inﬂuences that
are ubiquitous in the B cell lineage of the transgenic animals:
overexpression of MYC and stimulus by an autoantigen. Thus,
a vast population of cells may be predisposed to tumor
progression. Indeed, it is remarkable that the resulting
tumors are composed of only a ﬁnite number of clones,
suggesting the occurrence of clonal selection for tumorigenic
events beyond those imposed experimentally. The results
contrast sharply with the innumerable clones that proliferate
to produce a relatively indolent disease in MRL
lpr/lpr mice, a
proliferation that is itself driven by autoimmunity .
A variety of circumstantial evidence has implicated anti-
genic stimulus in the genesis of BL [83]. First, chronic
infection with malaria in Africa is associated with an
increased incidence of BL and accelerated progression of
the disease [84,85]. Second, the possibility of sustained
antigenic stimulus is raised by the mature, activated
immunophenotype characteristic of BL cells [86]. Third, the
sequences for the immunoglobulin molecules in many NHL,
including BL, bear somatic mutations of the sort that
normally arise during the process of afﬁnity maturation [8–
14] If antigenic stimulation does play a role in the genesis of
human BL, it would be in cooperation with MYC, whose
activation by chromosomal translocation is a general feature
of the tumor [87]. Our results with mouse models suggest that
the hypothetical role of antigenic stimulus in the patho-
genesis of BL should be pursued further.
The Response of Murine BCLs to Immunosuppressants
We have shown that antigenic stimulus can apparently
contribute to the establishment and maintenance of B-cell
lymphomas in mice. The tumors that arose in the El-MYC/
BCR
HEL/sHEL and MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL
mice expressed a neo-autoantigen (sHEL), which provided
an autoimmune stimulus to the tumor cells. This in turn
allowed the tumors to become self-sufﬁcient and retain
continuous cognate antigen stimulation upon transplanta-
tion. This notion was further supported by experiments in
which the signaling components of the BCR were genetically
disrupted with shRNAs.
The requirement for antigen in turn suggested that the
tumors might respond to pharmacological interruption of
signaling from the BCR. This proved to be the case: treatment
with cyclosporin, FK506, or rapamycin elicited prolonged
remissions. These results conform to the view that antigen-
induced signaling from the BCR was involved in the genesis of
the tumors. We recognize, however, that none of the
immunosuppressants acts exclusively on signaling from the
BCR and, as a result, each might inhibit tumors by a different
means [88–90]. For example, it has been reported that
rapamycin can inhibit angiogenesis in certain solid tumors
[91], whereas other immunosuppressants failed to demon-
strate this inhibition. In contrast, rapamycin, cyclosporin,
and FK506 all inhibit signaling from the BCR [92–94], and all
three elicited remissions of El-MYC/BCR
HEL/sHEL and
MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL tumors. Moreover, this
uniform effect of the three immunosuppressants did not
extend to tumors in which antigen stimulus ostensibly played
no role (El-MYC and El-MYC/BCR
HEL).
We conclude that the therapeutic effects of immunosup-
pressants reported here for the BL model probably reﬂect the
role of antigen-induced signaling from the BCR in the
pathogenesis of the tumor. Tactics that interrupt expression
of signaling from the BCR might also be useful in the
treatment of human lymphomas that express the receptor.
Methods
Transgenic mice and transplantation of tumors. Mice carrying the
El-MYC transgene have been described previously [20] and were
obtained from the Jackson Laboratory. These mice express MYC in a
B cell–speciﬁc manner, beginning at the Pre/Pro-B cell stage. The
TRE-MYC and MMTV-rtTA mice have been described previously
[21,23]. We crossbred these strains to combine the two transgenes in a
single strain (MMTV-rtTA/TRE-MYC), in which the B cell–speciﬁc
expression of the MYC transgene can be repressed by the admin-
istration of tetracycline or doxycycline. We also used both BCR
HEL
mice, which express a pre-rearranged murine BCR from the
endogenous immunoglobulin promoter, and sHEL mice, which
ubiquitously express a transgene for the soluble form of soluble
HEL under the control of the metallothionein promoter. These two
strains have been described previously [25] and were generously
provided by Jason Cyster (University of California, San Francisco).
We also used a strain of mice in which a previously rearranged IgH
VDJ sequence was knocked into the IgH locu [95]. When used in
combination with another strain, encoding an IgL transgene (Lt-tg),
those bigenic mice generate about 30% HEL-speciﬁc B cells, as
previously describe[95]5]. Those two strains of mice were kindly
provided by Jason Cyster, at UCSF. All transgenic mouse lines were
maintained on a C57/BL6 background, and were genotyped by PCR as
previously described [20,25,96]. All animals were maintained in
accordance with the guidelines of the Committee on Animal
Research at the University of California, San Francisco, and the
National Research Council.
Adoptive transfers of cells and transplantation of tumors were
done by injecting 10
6 cells intravenously (unless otherwise indicated)
into syngeneic (C57/BL6) females ranging in age from 4–6 wk. For the
experiments that involved tumor cells obtained from MMTV-rtTA/
TRE-MYC/BCR
HEL/sHEL tumors, the recipient mice were sublethally
irradiated (450 rads) in order to overcome some remaining allogeneic
differences between the two strains.
Assessment of tumorigenesis. The emergence of tumors was
followed in three ways: (i) physical examination of living animals
and necropsy of deceased animals, particularly to detect enlargement
of lymphoid organs and viscera; (ii) counting the total number of cells
in organs; and (iii) the speciﬁc enumeration of B cells carrying cell-
surface receptor for the antigen HEL. Three pairs of lymph nodes
were collected each time (two inguinal, two axillary, and two brachial
lymph nodes). These lymph nodes were pooled and processed into
single-cell suspensions. Spleens and thymii were also collected and
used to generate single-cell suspensions. Each spleen or thymus was
individually ground on a 60-lm wire mesh screen (Sigma). The red
blood cells were lysed in TAC buffer (0.017 M Tris, pH 7.65, and 0.135
MN H 4Cl), as previously described [95], and the resulting pellets were
resuspended in complete lymphocyte media, which consists of
RPMI1640 þ 10% heat inactivated fetal calf serum, supplemented
with L-glutamine, penicillin/streptomycin, nonessential amino acids,
2 mM HEPES, 2mM sodium pyruvate, and 10 mM b-mercaptoeatha-
nol (all obtained from Invitrogen). Single-cell suspensions were
counted with a Coulter counter (Coulter Diagnostics). The percent-
age of viable cells was determined by uptake of 7-aminoactinomycin
D (7AAD) and ﬂow cytometry. The values for total cell numbers were
used to derive the number of viable cells by multiplying percentage of
viable cells (obtained from the 7AAD analysis) by the total number of
cells (obtained from the Coulter counter analysis), and dividing by
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of trypan-blue excluding cells in a hemocytometer.
To determine the number of B cells carrying the BCR
HEL
transgene, single-cell suspensions were stained with antibodies to
B220 and IgM
a (both obtained from Pharmingen Laboratories),
followed by ﬂow cytometric analysis. The number of BCR
HELþB cells
was determined by multiplying the percentage of B220þ/IgM
aþ cells
(obtained from the FACS analysis) by the number of total viable cells
and dividing by 100. These values were compared to stains performed
using a pan-speciﬁc antibody to IgM (Pharmingen Laboratories). This
approach was used to determine the number of BCR
HEL expressing
cells in all the cases where the mice were on a C57/BL6 background,
where the allotype expressed is normally IgM
b. For the mice in which
the genetic background was mixed (all the experiments that involved
the MMTV-rtTA/TRE-MYC transgenes), the number of BCR
HEL-
expressing cells was determined by HEL binding. Single-cell
suspensions were incubated with HEL (1 mg/ml, obtained from
Sigma) in FACS buffer. These cells were washed and incubated with
Hy9-biotin, an HEL-speciﬁc monoclonal antibody (kindly provided
by Jason Cyster, UCSF), followed by streptavidin-PE and B220-FITC
(both obtained from Pharmingen Laboratories).
Phenotypic analysis of cells. The surface phenotype of cells
present in the lymphoid organs of normal and tumor-bearing mice
was analyzed by ﬂow cytometry. Single cell suspensions were
prepared from the lymph nodes, spleens, thymus, and bone marrow.
The cell suspensions were incubated with 1:50 dilutions of antibodies
on ice for 30 min, and were then washed in FACS buffer (1% BSA in
PBS þ 0.05% sodium azide) and ﬁxed in PBS containing 1%
paraformaldehyde. Cells were stained with antibodies to one or
more of the following markers: B220, Thy1.2, Mac-1, IgM (pan), IgM
a,
IgM
b, IgD (pan) and IgD
a, CD4, CD5, CD8, CD19, CD21, CD23, CD25,
CD44, CD62L, CD69, CD80, and/or CD86 (all obtained from BD-
Pharmingen). Binding of HEL to B cells was assessed by incubating
cell suspensions with 1 mg/ml HEL (Sigma) in FACS buffer. The cells
were then washed and incubated with Hy9-biotin, followed by
Streptavidin-PE (BD-Pharmingen).
Molecular analysis of tumor clonality. To determine the clonal
composition of the tumors, we adapted a protocol that has been
described previously [97]. Genomic DNA was extracted from 10
6 cells
(from either spleen or lymph nodes) using the Quiagen genomic DNA
mini-kit (Quiagen), following the manufacturer’s speciﬁcations. 200
ng of genomic DNA was used for a nested PCR reaction. The ﬁrst
reaction consisted of 5 ll of 10X Taq buffer (Gibco/Invitrogen), 4 llo f
50 mM MgCl2, 2.5 ng of VH-speciﬁc primer, 2.5 ng of JH-speciﬁc
primer, 2.5 nM dNTPs (Roche Diagnostics) and 2.5 U of Taq
polymerase (Roche Diagnostics) and distilled-deionized water to a
ﬁnal volume of 50 ll. The reactions were placed in a thermal cycler
(MJ-Research) and subjected to a PCR cycle as previously described
[97]. A sample of 2 ll from the ﬁrst reaction was used as a template for
the second reaction of the nested PCR. This reaction was conducted as
the ﬁrst one, except that the primer pairs encoded sequences within
the initial set used earlier. The sequences for all the primers used have
been previously described [96]. The PCR reaction products were
fractionated in a 2% agarose/TAE gel, stained with ethidium bromide.
Some of the PCR products were cloned using a TOPO-TA cloning kit
(Invitrogen Laboratories), following manufacturer’s speciﬁcations,
then sequenced using the Big Dye terminator cycle sequencing kit
(Applied Biosystems), following manufacturer’s speciﬁcation, at the
UCSF General Clinical Research Centers core facility.
Disruption of gene expression by shRNA in tumor cells. We used
the Reynolds algorithm [98] and pSICO oligomaker software [35] in
order to design the optimal target shRNA sequences. Those core 19-
mer sequences were incorporated into the oligonucleotides designed
to contain the stem and loop portions of the shRNA to be cloned into
the vector pLL3.7 [36]. Cloning was performed as previously
described [36]. The speciﬁc sequences we used to disrupt expression
of murine Iga,I g b or the control (ﬁreﬂy luciferase) have been
described elsewhere [95].
All constructs presented here were initially validated for their
ability to speciﬁcally knock down the expression levels of the protein
of interest by transduction of two BCLs that we generated from the
mouse models presented here. The two types of B cell lines we
generated were derived from El-MYC/BCRHEL (DBL: double trans-
genic B cell lymphoma) and El-MYC/BCR
HEL/sHEL (TBL: triply
transgenic B cell lymphoma) primary murine tumors. DBL and TBL
cell lines were generated by passive selection from El-MYC/BCR
HEL
and El-MYC/BCR
HEL/sHEL primary murine tumors, respectively.
Tumor B cell lines were grown in C10 (RPMI, 10% FBS (HyClone),
2 mM L-glutamine (Invitrogen) 100 units/ml penicillin G and
streptomycin sulfate (Invitrogen), 10 mM HEPES, 0.1 mM MEM
non-essential amino acids (Invitrogen), and 0.55 mM b-mercaptoe-
thanol (Invitrogen)). The GFPþ fraction of the transduced cell
population was used for either Western blotting or ﬂow cytometric
analysis of protein expression.
To generate infectious viral particles, we used 293FT cells as a
packaging system that had been previously described [99]. 293FT cells
were grown in D10 media (DMEM, 10% FBS (HyClone), 2 mM L-
glutamine (Invitrogen), 100 units/ml penicillin and streptomycin
(Invitrogen), and 0.1 mM MEM non-essential amino acids (Invitro-
gen). 293FT cells grown to 60% conﬂuency in 60-mm dishes were
transfected with 5 lg pLL3.7, 3.3 lg pMDLg/pRRE, 1.3lg pRSV-REV,
and 1.9lg pMD.G [99] overnight using calcium-phosphate methods, as
described previously [36]. Media were replaced with 4.5 ml fresh D10
the following morning.
Infections were performed as previously described [35]. Brieﬂy,
supernatants from 293FT cells were harvested 2 d after transfection
and replaced with fresh D10. Viral supernatants were passed through
a 0.45 lm ﬁlter and brought to a ﬁnal concentration of 8 lg/ml
polybrene and 10 mM HEPES, pH 7.4. These supernatants were
overlayed on 2310
5 DBL and TBL cells and spun at 2,000 rpm for 1 h
at 25 8C. Following spinfection, viral supernatants were removed and
replaced with fresh C10. Infections were repeated the following day (3
d after transfection).
For the in vitro assays used to determine whether the disruption of
a gene product affected the competitiveness of a tumor cell, we used a
mixed of transduced and nontransduced cells. The efﬁciency of viral
transduction of DBL and TBL cell lines was initially evaluated 48 h
after the second spin infection. We subsequently tracked infected
cells for two weeks post-infection. For analysis, we normalized all
infection efﬁciencies to the 48-h time point, and further normalized
each day to the infection rate for the pLL3.7 alone.
Therapeutic trials. Groups of six mice were used for each of the
experimental protocols. Four mice bearing transplanted tumors, and
two age- and sex-matched wild-type mice were treated with the same
drug and equal frequency. The transplant-recipient mice were held
until tumors became clinically apparent (approximately 100 d for the
El-MYC tumors, 58 d for the El-MYC/BCRHEL tumors, 21 d for the
El-MYC/BCR
HEL/sHEL tumors, and 14 d for the MMTV-rtTA/TRE-
MYC/BCR
HEL/sHEL tumors). The mice then received daily injections
of the indicated agents for 7 d. Mice were either euthanized 24 h after
the last injection of drug, or held indeﬁnitely to ascertain survival.
Lymph nodes, spleens and bone marrows were collected and
processed to generate single-cell suspensions. The cells were counted
as described above. An aliquot from the cell suspensions was stained
with antibodies for B220, Thy 1.2, Mac-1, IgM
a, B7–2, and CD69, in
order to determine the proportion of B cells, T cells, and myeloid
cells, as well as the activation status of the HEL-reactive B cells.
Treatments were performed with cyclosporin A (Bedford Laborato-
ries) (2 mg/kg/day), FK506 (Prograf, Fujisawa Healthcare) (2 mg/kg/
day), rapamycin (Biomol) (2 mg/kg/day), and cyclophosphamide
(Bristol-Myers Squibb) (1 mg/kg/day). The therapeutic agents were
suspended in PBS, sterilized by ﬁltration through a 0.22lm
membrane, and administered intravenously through the tail vein.
Tissue processing and histology. Normal and tumor tissues were
ﬁxed in 10% formalin and embedded in parafﬁn. Sections (4lm) were
stained with hematoxylin-eosin. Images were acquired with a CCD
camera mounted on a phase-contrast microscope.
Supporting Information
Figure S1. Immunophenotype of B Cell Tumors
Flow cytometric analysis was performed on spleen cells from a wild-
type mouse (orange trace), a tumor-bearing El-MYC/BCR
HEL mouse
(blue trace), or a tumor-bearing El-MYC/BCR
HEL/sHEL mouse (pink
trace), and cells from a jaw tumor in an MMTV-rtTA/TRE-MYC/
BCR
HEL/sHEL mouse (green trace). Staining for the indicated surface
markers was compared to unstained spleen cells from wild-type mice
(ﬁlled purple trace).
Found at doi:10.1371/journal.pbio.0060152.sg001 (2.28 MB TIF).
Figure S2. Clonality of Tumors
Genomic DNA was analyzed for VH to DJH rearrangements as
described in the Methods section. We examined rearrangements of 16
different combinations of four V region genes (lanes numbered 1–4,
as follows: 1 corresponds to 36–6, 2 to 81X, 3 to Q-52, and 4 to J558).
These were tested in combination with the four JH genes listed in the
ﬁgure (JH1–4). The arrows in the lower left corners of the panels
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germ line conﬁguration. All of the rearranged VDJH products
migrated more slowly in the gel. The data are representative of three
different matched pairs of primary and transplanted tumors, for each
tumor type.
(A) Wild-type spleen.
(B) Spleen cells from a 6 month old MRL
lpr/lpr mouse with
lymphoproliferative disease.
(C) Spleen tumor from an El-MYC/BCR
HEL mouse.
(D) Spleen cells from a mouse 60 d after receiving a transplant of the
cells analyzed in (C).
(E) Spleen tumor from an El-MYC/BCR
HEL/sHEL mouse.
(F) Spleen cells from a mouse 23 d after receiving a transplant of the
cells analyzed in (E).
(G) Jaw tumor from an MMTV-rtTA/TRE-MYC/BCR
HEL/sHEL mouse.
(H) Spleen cells from a mouse 14 d after receiving a transplant of cells
analyzed in (G).
Found at doi:10.1371/journal.pbio.0060152.sg002 (4.27 MB TIF).
Figure S3. Regulation of TRE-MYC Transgene Expression by
Docycycline in B Cells Obtained from MMTV-rtTA/TRE-MYC/
BCRHEL Transgenic Mice
Splenic B cells were obtained from said mice, activated in vitro for 3 d
with antibodies to IgM and CD40, in the presence or absence of
docycycline. Cells were then lysed and subjected to SDS-PAGE
electrophoresis and western blot analysis. The antibody used to
detect human MYC, encoded by the transgene was 9E10.
Found at doi:10.1371/journal.pbio.0060152.sg003 (995 KB TIF).
Figure S4. Murine Burkitt-Like Tumors Are Composed of Post-GC B
Cells
Post-GC nature of Burkitt-like tumors: The large BCLs in humans,
including BL, are typically derived from post-GC B cells. Based on
histological appearance and cell-surface markers, we suggested that
the tumors arising in El-MYC/BCR
HEL/sHEL and MMTV-rtTA/TRE-
MYC/BCR
HEL/sHEL mice resembled BL (see Results section). To
further authenticate the resemblance, we sought evidence that the
mouse tumors were derived from post-GC B cells. We used three
criteria to deﬁne whether the cells derived from the murine BCLs in
our models have undergone a GC reaction. First, evidence of
immunoglobulin class switching; second, hypermutation in the
nucleic acid sequence encoding for the BCR hypervariable regions
expressed by the tumor cells; and third, expression of genes
associated with the GC process.
We could not explore class switching and somatic mutation with
the mouse strains used to this point, because the BCR
HEL transgene
was not controlled by the internal elements of the IgH locus, was
conﬁgured to generate mature IgM and IgD isotypes, and could not
undergo further class switching. Instead, we obtained two additional
genetically modiﬁed mouse strains that would enable this analysis
with a deﬁned antigenic speciﬁcity: one in which the hypervariable
region for the IgH speciﬁc to HEL had been recombined into the
corresponding site of the IgH locus, named VDJki [95], and another
that harbored a transgene encoding the IgL that would normally pair
with the corresponding IgH in the HEL-speciﬁc hybridoma from
which the hypervariable region was cloned, named Lt-tg [95]. Those
two alleles have previously been shown to give rise to HEL-speciﬁc B
cells that can undergo a GC reaction, as determined by their ability to
produce HEL-speciﬁc antibodies that had class-switched [95]. The key
advantage of using the VDJki/Lt-tg mice to generate HEL-speciﬁc B-
cells over BCRHEL transgenic mice is the ability of the former to
undergo somatic mutations and class switching in a GC-dependent
manner, since the HEL-speciﬁc components were integrated into the
normal locus [95].
In order to facilitate this strategy, we created a strain of mice (El-
MYC/VDJki/Lt-tg/sHEL) that incorporated the knock-in allele for
generating HEL-speciﬁc B cells, and used this strain to examine
whether the cells that composed the resulting BL-like tumors had
been selected in the GC. The mice developed BCLs at about 50–64 d
after birth, with complete penetrance (unpublished data). The
resulting tumors were present in the lymph nodes, spleen, thymus,
and bone marrow, and also inﬁltrated other organs, including the
liver, lungs, kidney, and central nervous system (unpublished data).
The tumor cells were B220þ, CD19þ, IgMþ, CD69þ, B7–2þ, CD21þ,
CD23-, and PNAþ, consistent with a mature, activated, post-GC
phenotype, and identical to what we had observed previously with the
El-MYC/BCR
HEL/sHEL mice (Table 1). In addition, the tumors that
arose from El-MYC/VDJki/Lt-tg/sHEL mice displayed the character-
istic ‘‘starry sky’’ histopathogy, and could be readily transplanted into
unmanipulated, syngeneic recipient mice (unpublished data). We also
tested the dependence of the tumors that arose in El-MYC/VDJki/Lt-
tg/sHEL mice upon continuous BCR-derived signals. We used the
shRNA-mediated knockdown approach to target Iga and Igb,a s
shown in Figure 4. We observed that the tumors that developed in El-
MYC/VDJki/Lt-tg/sHEL mice required Iga or Igb expression for their
maintenance in vitro, suggesting that they depend upon continuous
antigenic stimulation (unpublished data).
To test whether the cells that compose the tumors obtained from
the El-MYC/IgH129ki/Lt-tg/sHEL mice had undergone a GC reaction,
we examined three criteria: the presence of HEL-speciﬁc immuno-
globulins in the sera of the tumor-bearing mice that are of different
classes (IgM, IgG, and IgA); the presence of point mutations in the
VDJ joint sequences of the IgH129ki allele, consistent with somatic
mutations that occur in the germinal center during the process of
afﬁnity maturation; and the expression of two GC-associated genes,
Bcl-6 and activation-induced cytidine deaminase (AID).
The ﬁrst difference that we observed between the tumors that
developed in El-MYC/IgH129ki/Lt-tg/sHEL mice and those from El-
MYC/BCR
HEL/sHEL mice was the secretion of additional Ig types (A).
In addition to HEL-speciﬁc IgM (found also in the tumors expressing
the BCR
HEL transgene), we also detected HEL-speciﬁc IgG1, IgG2,
IgG3, and IgA, as expected from the class switching that occurs in the
GC reaction. In addition, not all the tumor-bearing mice had all Ig
isotypes, suggesting clonal differences among the different tumors.
We ampliﬁed the VDJ joint sequence from eight tumors obtained
from El-MYC/IgH129ki/Lt-tg/sHEL mice by PCR-based methods, then
cloned the ampliﬁed products and sequenced the contents obtained
from 120 independent colonies. Every sequence obtained from those
tumors contained mutations in the VDJ sequence of the IgH129ki
allele. Moreover, we found several clones that contained the identical
patterns of mutations (B). By contrast, we noticed one mutation
among 20 alleles we sequenced from a normal, healthy IgH129ki
mouse, which we attribute to a PCR error.
While the class switching and somatic mutation data should sufﬁce
to formally prove that the BL-like tumors are composed of post-GC
cells, we also sought to determine whether those cells express
transcripts of two genes that are normally associated with the GC
reaction. Accordingly, we developed assays for real-time, semi-
quantitative RT-PCR for Bcl-6 and AID. Bcl-6 is highly expressed in
human DLBL, and a loss of function mutation in mice was shown to
lead to defective formation of GC [100]. AID was shown to be critical
for the processes of class-switch recombination and somatic mutation
that are carried out during a GC reaction [101]. Our results show that
8/8 tumors expressed high levels of Bcl-6 transcripts, and 5/8 tumors
expressed high levels of AID mRNA relative to normal splenic B cells
(C). In addition, we were also able to detect high levels of Bcl-6 mRNA
in tumors that developed in El-MYC/BCR
HEL/sHEL mice, although we
were not able to detect AID transcripts in those tumors (n ¼ 10) (C).
We did not observe any detectable levels of mRNAs for either AID or
Bcl-6 in the tumors that developed in El-MYC/BCR
HEL mice (C).
These data allow us to conclude that the MYC-driven, antigen-
dependent BCLs in the El-MYC/IgH129ki/Lt-tg/sHEL mice were
composed of post-GC cells, in accord with their other resemblances
to BL. Thus, by diverse measures, the tumors in El-MYC/IgH129ki/Lt-
tg/sHEL mice provide a reasonable facsimile of BL. In addition, the
conclusions obtained from these studies likely extend to our
additional mouse models of BL.
(A) Analysis of class-switching in HEL-speciﬁc BCLs. Groups of
eight mice for each genotype described were used for these assays.
The sera samples were examined for the presence of HEL-speciﬁc
immunoglobulins using a solid-phase either bled at 8 wk of age (all of
the control groups), or upon presenting of clinical signs of disease
(for El-MYC/BCRHEL/sHEL and VDJIki/Lt-tg/BCRHEL/sHEL mice).
ELISA assay. Sera were obtained from groups of eight mice of the
speciﬁed genotypes and assayed in triplicate by ELISA against HEL,
using isotype-speciﬁc secondary antibodies. The sera were obtained
from wild-type mice (column 1), naı ¨ve BCR
HEL mice (column 2),
BCR
HEL that were immunized with HEL emulsiﬁed in complete
Freund’s adjuvant 14 d prior to bleeding (column 3), naı ¨ve VDJki/Lt-
Tg mice (column 4), VDJki/Lt-Tg mice that were immunized with HEL
emulsiﬁed in complete Freund’s adjuvant 14 d prior to bleeding
(column 5), tumor-bearing El-MYC/BCR
HEL/sHEL mice (column 6), or
tumor-bearing VDJIki/Lt-tg/BCR
HEL/sHEL mice (column 7). The
results shown here are from one representative experiment of three.
(B) Analysis of somatic mutations in the immunoglobulin joint
sequence. We PCR-ampliﬁed and sequenced the VDJ-joint sequence
of the HEL-speciﬁc BCR in tumor-bearing mice in order to
PLoS Biology | www.plosbiology.org June 2008 | Volume 6 | Issue 6 | e152 1222
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BL tumors. Cells were obtained from tumor-bearing El-MYC/VDJki/
Lt-Tg/sHEL mice and used to obtain genomic DNA. The DNAs were
used to perform a PCR reaction with primers surrounding the IgH
VDJ joint region used for generating the knock-in mutation. PCR
products were cloned into TOPO cloning vectors and sequenced. The
bold, underlined letters in the sequence show mutations found in the
tumors, as opposed to the sequences obtained from a VDJki/Lt-Tg
mouse (20 clones), presented at the bottom of the table. We only
detected one point mutation among the 20 clones that we sequenced
from normal VDJki/Lt-tg B-cells.
(C) Detection of mRNAs encoding Bcl-6 and AID in tumors
obtained from El-MYC/VDJki/Lt-tg/sHEL transgenic mice. Cells were
obtained from either normal VDJki/Lt-tg mice (column 1), tumor-
bearing El-MYC mice (column 2), or tumor-bearing El-MYC/VDJki/
Lt-Tg/sHEL mice (columns 3–10). All cell suspensions were depleted
from their T cells, and used to generate RNA with a Trizol reagent.
These RNAs were used to generate cDNAs in vitro with random
primers. The resulting cDNAs were then used for real-time, semi-
quantitative RT-PCR, using SYBR green for ﬂuorescent detection. We
used oligonucleotides speciﬁc for AID or Bcl-6, as previously
reported [102, 103]. The values presented were standardized to the
levels of two housekeeping genes (GAPDH and L32). The results
presented here are from one assay representative of three independ-
ent assays.
Found at doi:10.1371/journal.pbio.0060152.sg004 (4.05 MB TIF).
Table S1. Comparison of Human and Mouse Tumors
Found at doi:10.1371/journal.pbio.0060152.st001 (37 KB DOC).
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